Results 71 to 80 of about 2,582 (154)

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

Annals of Gastroenterological Surgery, Volume 10, Issue 2, Page 325-335, March 2026.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban   +4 more
wiley   +1 more source

Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospective Study

Annals of Gastroenterological Surgery, Volume 10, Issue 1, Page 251-262, January 2026.
We aimed to refine treatment strategies for resected cases of pancreatic ductal adenocarcinoma in patients with unexpectedly uncovered postoperative noncurative factors. Cases with unexpected postoperative uncovering noncurative factors had significantly poorer prognoses than those without such factors.
Hiroto Matsui, Naoki Ikenaga, Masafumi Nakamura, Takaaki Tatsuguchi, Shingo Kozono, Hirohisa Okabe, Hiromitsu Hayashi, Tomohiko Adachi, Susumu Eguchi, Kazuaki Hashimoto, Toru Hisaka, Takao Ide, Hirokazu Noshiro, Teijiro Hirashita, Atsushi Miyoshi, Atsushi Nanashima, Masatoshi Kajiwara, Tomoharu Yoshizumi, Yasuhisa Mori, Hiroaki Nagano, Kyushu Study Group of Treatment for Pancreatobilliary Cancer   +20 more
wiley   +1 more source

Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy

Annals of Gastroenterological Surgery, Volume 10, Issue 1, Page 6-14, January 2026.
ABSTRACT Background Nivolumab‐including chemotherapy (nivo‐CTX) for stage IV gastric cancer (GC) may increase the chance of conversion surgery but risk of immune‐related adverse events (irAEs) during perioperative period remains unclear. Methods We examined irAEs in 36 patients with marginally resectable GC who received nivo‐CTX followed by surgery ...
Masashi Nishino, Takaki Yoshikawa, Hirokazu Shoji, Yuki Takenaka, Maho Takuwa, Yurina Fujisaki, Rei Ogawa, Takeyuki Wada, Tsutomu Hayashi, Yukinori Yamagata, Nobuyoshi Hiraoka, Yasuyuki Seto   +11 more
wiley   +1 more source

Ultrasound-guided microwave ablation for metastatic breast cancer: a 3-year follow-up case report and review of the literature

Frontiers in Oncology
This case describes the application of ultrasound-guided microwave ablation (MWA) in the management of a solitary breast metastatic lesion in a 59-year-old female with a history of lung adenocarcinoma.
Juan Li, Binru Xia, Xiaojia Zhang, Lu Wang, Tingting Li, Jie Zou, Man Lu   +6 more
doaj   +1 more source

Feedback regulation between histone H3 lysine 18 lactylation and TROP2‐mediated glycolysis drives metastatic progression of colorectal cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
TROP2 is upregulated in CRC metastasis and promotes lactate overproduction via YBX1‐HIF‐1α signalling. TROP2 signalling induces H3K18la at metastasis genes promoters in CRC and promotes their expression. AccLactate sustains TROP2 expression in CRC cells via H3K18la Acriflavine suppresses TROP2‐driven CRLM by targeting the H3K18la/TROP2 feedback loop ...
Weifeng Wang, Yuxiang Deng, Weihao Li, Ruowei Wang, Chi Zhou, Yanbo Xu, Jiahua He, Le' en Liao, Jin Lan, Long Yu, Da Kang, Weili Zhang, Qingjian Ou, Zhizhong Pan, Yujing Fang, Peirong Ding, Junzhong Lin, Jianhong Peng   +17 more
wiley   +1 more source

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood.
Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer‐Sakel, Harald Lahner   +6 more
wiley   +1 more source

Case: Testicular oligometastasis from prostate cancer — Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy

, 2017
Testicular oligometastasis secondary to prostate cancer is rare. We present a case where a patient with locally advanced prostate cancer was treated with high-dose external beam radiotherapy and two years of androgen-deprivation therapy, followed by ...
Christopher M. Davidson, Chan-Kyung J. Cho, Samantha Sigurdson, Michael Leveridge, Aamer Mahmud   +4 more
core   +1 more source

Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies

ESMO Gastrointestinal Oncology
International treatment guidelines recommend tumor resection for patients with oligometastatic colorectal cancer (CRC). Despite this, recurrence occurs in ∼60% of patients post-surgery, indicating that the role and optimal type of perioperative systemic ...
E. Oki, R. Nakanishi, K. Ando, I. Takemasa, J. Watanabe, N. Matsuhashi, T. Kato, Y. Kagawa, M. Kotaka, K. Hirata, M. Sugiyama, T. Kusumoto, Y. Miyamoto, K. Toyosaki, J. Kishimoto, Y. Kimura, T. Yoshizumi, Y. Nakamura   +17 more
doaj   +1 more source

Evaluation of the Clinical Efficacy of Intensity-Modulated Radiotherapy Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Extrahepatic Oligometastasis and Prognostic Factors for Patient Survival

, 2023
Yunxiu Luo,1,* Xiaopeng Huang,2,* Jiawei Chen,2 Shuai Zhang2 1Department of Radiation Oncology, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan Province, 570311, People’s Republic of China ...
Chen J, Huang X, Luo Y, Zhang S
core  

Case Report: Exceptional long-term survival in metastatic pancreatic ductal adenocarcinoma after repeated high-dose hypofractionated lesion-directed radiotherapy

Frontiers in Oncology
Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and survival beyond a decade is exceptional. We report a 59-year-old man with stage IV PDAC presenting with oligometastatic disease involving a pancreatic head/uncinate primary ...
Mingli Ding, Mingli Ding, Zhuo Song, Yupeng Di, Yingjie Wang, Gang Ren   +5 more
doaj   +1 more source